Durability of Symptom Reductions Associated with Use of HIRREM by Military Personnel with Traumatic Stress (I8.007)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: Evaluate the effects, and durability, associated with use of High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM®) among subjects enrolled in a pilot study for symptoms of military-related traumatic stress (MTS). Background: Symptoms associated with MTS include insomnia, depression, and anxiety. HIRREM is a noninvasive, closed-loop acoustic stimulation technology that identifies dominant brain frequencies and translates them in real time into audible tones of variable pitch and timing, to support self-updating and self-optimization of brain activity. We report interim MTS symptom outcomes. Methods: Fourteen male service members, or Veterans, mean (SD) age 40.9 (7.0), with MTS symptoms from 1-12 years, received 19.6 (1.0) HIRREM sessions over 12 days. Symptom inventories collected before, immediately after (n = 14, Visit 2, V2), and at 1 (n = 13, V3), 3 (n = 8, V4), and 6 (n = 3, V5) months after completion of HIRREM, included inventories of traumatic stress (PCL-M), insomnia (ISI), depression (CES-D), and anxiety (GAD -7). Paired t-tests were performed. Results: Mean change in symptom scores compared to baseline values included PCL-M [V2, -12.7 (8.4), p < 0.01; V3, -19.1 (12.1), p < 0.01; V4, -19 (17.3), p = 0.02)], ISI [V2, -5.3 (5.0), p < 0.01; V3, -8.9 (5.5), p < 0.01; V4, -7.6 (7.7), p = 0.03], CES-D [V2, -13.7 (9.1), p < 0.01; V3, -17.5 (10.2), p < 0.01; V4, -17.8 (14.6), p = 0.01]; and GAD-7 [V2, -5.1. (4.1), p < 0.01; V3, -5.8 (4.8), p < 0.01; V4, -7 (6.8), p = 0.02]. Only 3 have reached 6 months, but trends for benefit continue. There were no adverse events or dropouts. Conclusions: These interim results show reduced symptoms of MTS, including insomnia, depression, and anxiety, with durability through 3 months post-HIRREM. Confirmation of these results could suggest an alternative approach to reduce MTS symptoms.
Disclosure: Dr. Tegeler has nothing to disclose. Dr. Tegeler has nothing to disclose. Dr. Cook has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Lee has received personal compensation for with activities with Brain State Technologies, LLC., as an employee. Dr. Shaltout has nothing to disclose.
Monday, April 18 2016, 1:00 pm-5:30 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.